Table 9.
Multivariable hazard ratios (HR) and 95 % confidence intervals (CIs) for risk of ovarian cancer by tertiles of 16-pathway metabolites
| Estrogen/EM | Cases (n = 67) | Subcohort (n = 416) | HR (95 % CI) |
|---|---|---|---|
| 16-Pathway metabolites | |||
| Estriol (E3) | |||
| T1 | 17 | 137 | 1.00 |
| T2 | 19 | 138 | 0.83 (0.41, 1.68) |
| T3 | 31 | 141 | 1.59 (0.82, 3.09) |
| p trend | 0.15 | ||
| 16α-Hydroxyestrone | |||
| T1 | 16 | 137 | 1.00 |
| T2 | 26 | 137 | 1.48 (0.75, 2.95) |
| T3 | 25 | 142 | 1.34 (0.67, 2.65) |
| p trend | 0.43 | ||
| 17-Epiestriol | |||
| T1 | 18 | 137 | 1.00 |
| T2 | 22 | 138 | 1.18 (0.60, 2.34) |
| T3 | 27 | 141 | 1.49 (0.76, 2.92) |
| p trend | 0.24 | ||
| 16-Epiestriol | |||
| T1 | 17 | 137 | 1.00 |
| T2 | 25 | 138 | 1.36 (0.69, 2.68) |
| T3 | 25 | 141 | 1.57 (0.80, 3.09) |
| p trend | 0.19 | ||
| 16-Ketoestradiol | |||
| T1 | 19 | 137 | 1.00 |
| T2 | 19 | 138 | 0.87 (0.43, 1.77) |
| T3 | 29 | 141 | 1.39 (0.74, 2.60) |
| p trend | 0.29 | ||
The following tertile categories (T1, T2, T3 pmol/L) determined based on the distribution of each estrogen or estrogen metabolite among the subcohort: estriol (<188.29, 188.29–306.39, >306.39), 16α-hydroxyestrone (<22.95, 22.95–35.14, >35.14), 17-epiestriol (<2.49, 2.49–3.95, >3.95), 16-epiestriol (<3.25, 3.25–5.85, >5.85), 16-ketoestradiol (<25.05, 25.05–39.20, >39.20); adjusted for clinic and trial participation status